Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis
Siskind D, Hahn M, Correll CU, et al. Diabetes Obes Metab. 2018 Sep 5. doi: 10.1111/dom.13522. (Review) PMID: 30187620
This systematic review of 3 studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) found that they are effective and tolerable for antipsychotic-associated body weight gain, particularly clozapine/olanzapine-treated patients. Although a bit too early to say for sure, GLP-1RAs may offer a useful adjunctive treatment for people taking antipsycotic medication.
https://plus.mcmaster.ca/EvidenceAlerts/NewArticles.aspx?Page=2&ArticleID=82404#Data